Asian investors back US stem cell company

A consortium led by RimAsia Capital Partners has invested $11m in NeoStem to help the company expand its activities in China. RimAsia's Eric Wei sees 'huge market potential' for stem cell therapies in the country.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this